mark_baker_photograph2

NICE appoints two new directors

pharmafile | March 7, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |ย ย Mark Baker, NICEย 

The National Institute for Health and Clinical Excellence (NICE) has appointed two new directors.

Professor Mark Baker will be the director of the centre for clinical practice and Alexia Tonnel will become the director of evidence resources.

The appointments follow the departure of the long-standing Professor Peter Littlejohns, who leaves to to take up an academic post, and the retirement of Dr Fergus Macbeth.

Prof Bakerโ€™s previous appointments include chief executive of Bradford teaching hospitals, director of R&D for the Yorkshire Region and director of the Yorkshire Cancer Network.

Advertisement

He has been involved in the NICE guidelines programme for almost a decade, has chaired two clinical guideline development groups and has worked since 2009 as a consultant adviser to NICE.

Alexia Tonnel has been working with NICE as programme director for the last two years, redesigning and managing the processes for the provision of content into NHS Evidence and leading the development of new products, such as the evidence updates.

Prior to joining NICE, she was a director with Deloitte where she advised clients in the healthcare and life sciences industries on policy and strategy development.

Tonnel will take up her position on 12 March and Professor Baker will take up his position on 2 April.

Related Content

Combination treatments: Takedaโ€™s Implementation Framework and the broader landscape

Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …

NICE recommends Pfizerโ€™s new once-weekly treatment for haemophilia B on NHS

Walton Oaks, 21stย May 2025ย โ€“ย Pfizer Ltd announced today that the National Institute for Health and Care …

Dual immunotherapy for bowel cancer now available under NHS

Dual immunotherapy, a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), has been granted extension in …

The Gateway to Local Adoption Series

Latest content